Your browser doesn't support javascript.
loading
Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies.
Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Sato, Naomi; Yamada, Hidetaka; Tanioka, Fumihiko; Nagashima, Makoto; Katoh, Ryoji; Satoh, Yasuo; Tagami, Megumi; Ujike, Hiroshi; Ozaki, Norio; Inada, Toshiya; Iwata, Nakao; Sora, Ichiro; Iyo, Masaomi; Yamada, Mitsuhiko; Kondo, Naoki; Won, Moo-Jun; Naruse, Nobuya; Uehara-Aoyama, Kumi; Itokawa, Masanari; Ohi, Kazutaka; Hashimoto, Ryota; Tanisawa, Kumpei; Arai, Tomio; Mori, Seijiro; Sawabe, Motoji; Naka-Mieno, Makiko; Yamada, Yoshiji; Yamada, Miki; Sato, Noriko; Muramatsu, Masaaki; Tanaka, Masashi; Irukayama-Tomobe, Yoko; Saito, Yuki C; Sakurai, Takeshi; Hayashida, Masakazu; Sugimura, Haruhiko; Ikeda, Kazutaka.
Afiliación
  • Nishizawa D; Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. nishizawa-ds@igakuken.or.jp.
  • Kasai S; Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. kasai-sy@igakuken.or.jp.
  • Hasegawa J; Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. hasegawa-jk@igakuken.or.jp.
  • Sato N; Department of Clinical Nursing, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan. naomi25@hama-med.ac.jp.
  • Yamada H; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan. naomi25@hama-med.ac.jp.
  • Tanioka F; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan. h-yamada@hama-med.ac.jp.
  • Nagashima M; Department of Pathology, Iwata City Hospital, Iwata, 438-8550, Japan. kyon8@juno.ocn.ne.jp.
  • Katoh R; Department of Surgery, Toho University Sakura Medical Center, Sakura, 285-8741, Japan. nagashima@sakura.med.toho-u.ac.jp.
  • Satoh Y; Department of Surgery, Toho University Sakura Medical Center, Sakura, 285-8741, Japan. ryochan@sakura.med.toho-u.ac.jp.
  • Tagami M; Department of Anesthesiology, Toho University Sakura Medical Center, Sakura, 285-8741, Japan. satoh-ane@sakura.med.toho-u.ac.jp.
  • Ujike H; Department of Anesthesiology, Toho University Sakura Medical Center, Sakura, 285-8741, Japan. tagami@sakura.med.toho-u.ac.jp.
  • Ozaki N; Ujike Nishiguchi Clinic, Okayama, 700-0024, Japan. hujike-10@t.okadai.jp.
  • Inada T; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. hujike-10@t.okadai.jp.
  • Iwata N; Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan. ozaki-n@med.nagoya-u.ac.jp.
  • Sora I; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. ozaki-n@med.nagoya-u.ac.jp.
  • Iyo M; Department of Psychiatry, Seiwa Hospital, Institute of Neuropsychiatry, Tokyo, 162-0851, Japan. inada@seiwa-hp.com.
  • Yamada M; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. inada@seiwa-hp.com.
  • Kondo N; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, 470-1192, Japan. nakao@fujita-hu.ac.jp.
  • Won MJ; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. nakao@fujita-hu.ac.jp.
  • Naruse N; Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. sora@med.kobe-u.ac.jp.
  • Uehara-Aoyama K; Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan. sora@med.kobe-u.ac.jp.
  • Itokawa M; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. sora@med.kobe-u.ac.jp.
  • Ohi K; Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. iyom@faculty.chiba-u.jp.
  • Hashimoto R; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. iyom@faculty.chiba-u.jp.
  • Tanisawa K; Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, 187-8553, Japan. mitsu@ncnp-k.go.jp.
  • Arai T; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. mitsu@ncnp-k.go.jp.
  • Mori S; Seimei Hospital, Fuji City, 417-0801, Japan. waveonlyjust@yahoo.co.jp.
  • Sawabe M; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. waveonlyjust@yahoo.co.jp.
  • Naka-Mieno M; Koujin Hospital, Nagoya, 463-8530, Japan. wonmj@hm10.aitai.ne.jp.
  • Yamada Y; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. wonmj@hm10.aitai.ne.jp.
  • Yamada M; Saitama Seishin-iryo Center, Kita-adachi, Saitama, 362-0806, Japan. naruse.nobuya@pref.saitama.lg.jp.
  • Sato N; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. naruse.nobuya@pref.saitama.lg.jp.
  • Muramatsu M; Kanagawa Psychiatric Center, Serigaya Hospital, Kanagawa, 233-0006, Japan. kums@ballade.plala.or.jp.
  • Tanaka M; Japanese Genetics Initiative for Drug Abuse (JGIDA), Tokyo, Japan. kums@ballade.plala.or.jp.
  • Irukayama-Tomobe Y; Schizophrenia and Depression Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan. itokawa-ms@igakuken.or.jp.
  • Saito YC; Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan. ohi@psy.med.osaka-u.ac.jp.
  • Sakurai T; National Hospital Organization, Yamato Mental-Medical Center, Nara, 639-1042, Japan. ohi@psy.med.osaka-u.ac.jp.
  • Hayashida M; Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan. hashimor@psy.med.osaka-u.ac.jp.
  • Sugimura H; Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University, Chiba University, and Fukui University School of Medicine, Osaka, 565-0871, Japan. hashimor@psy.med.osaka-u.ac.jp.
  • Ikeda K; Department of Genomics for Longevity and Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, 173-0015, Japan. kunpei-tanisawa@fuji.waseda.jp.
Mol Brain ; 8: 50, 2015 Aug 20.
Article en En | MEDLINE | ID: mdl-26289589
BACKGROUND: Many genetic and environmental factors are involved in the etiology of nicotine dependence. Although several candidate gene variations have been reported by candidate gene studies or genome-wide association studies (GWASs) to be associated with smoking behavior and the vulnerability to nicotine dependence, such studies have been mostly conducted with subjects with European ancestry. However, genetic factors have rarely been investigated for the Japanese population as GWASs. To elucidate genetic factors involved in nicotine dependence in Japanese, the present study comprehensively explored genetic contributors to nicotine dependence by using whole-genome genotyping arrays with more than 200,000 markers in Japanese subjects. RESULTS: The subjects for the GWAS and replication study were 148 and 374 patients, respectively. A two-stage GWAS was conducted using the Fagerström Test for Nicotine Dependence (FTND), Tobacco Dependence Screener (TDS), and number of cigarettes smoked per day (CPD) as indices of nicotine dependence. For the additional association analyses, patients who underwent major abdominal surgery, patients with methamphetamine dependence/psychosis, and healthy subjects with schizotypal personality trait data were recruited. Autopsy specimens with various diseases were also evaluated. After the study of associations between more than 200,000 marker single-nucleotide polymorphisms (SNPs) and the FTND, TDS, and CPD, the nonsynonymous rs2653349 SNP (located on the gene that encodes orexin [hypocretin] receptor 2) was selected as the most notable SNP associated with FTND, with a p value of 0.0005921 in the two-stage GWAS. This possible association was replicated for the remaining 374 samples. This SNP was also associated with postoperative pain, the initiation of methamphetamine use, schizotypal personality traits, and susceptibility to goiter. CONCLUSIONS: Although the p value did not reach a conventional genome-wide level of significance in our two-stage GWAS, we obtained significant results in the subsequent analyses that suggest that the rs2653349 SNP (Val308Ile) could be a genetic factor that is related to nicotine dependence and possibly pain, schizotypal personality traits, and goiter in the Japanese population.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tabaquismo / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Estudio de Asociación del Genoma Completo / Receptores de Orexina Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Brain Asunto de la revista: BIOLOGIA MOLECULAR / CEREBRO Año: 2015 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tabaquismo / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Estudio de Asociación del Genoma Completo / Receptores de Orexina Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Brain Asunto de la revista: BIOLOGIA MOLECULAR / CEREBRO Año: 2015 Tipo del documento: Article País de afiliación: Japón